Orchestra BioMed Holdings
OBIO64
$5.77arrow_drop_up0.91%$0.04
OBIO64
$5.77
arrow_drop_up0.91%Performance History
| Key Stats | |
|---|---|
| Open | $5.50 |
| Prev. Close | $5.44 |
| EPS | -1.60 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $218.24M |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 5.43 | 5.87 |
| 52 Week Range | 4.22 | 11.69 |
| Ratios | |
|---|---|
| EPS | -1.60 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
About Orchestra BioMed Holdings (OBIO)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. David P. Hochman
- Headquarters
- New Hope
- Employees
- 0
- Exchange
- NASDAQ
Keep an eye on Orchestra BioMed Holdings
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Orchestra BioMed Holdings's (OBIO) price per share?
The current price per share for Orchestra BioMed Holdings (OBIO) is $5.77. The stock has seen a price change of $0.05 recently, indicating a 0.92% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Orchestra BioMed Holdings (OBIO)?
For Orchestra BioMed Holdings (OBIO), the 52-week high is $11.69, which is 102.6% from the current price. The 52-week low is $4.22, the current price is 36.73% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Orchestra BioMed Holdings (OBIO) a growth stock?
Orchestra BioMed Holdings (OBIO) has shown an average price growth of -3.66% over the past three years. It has received a score of 85 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Orchestra BioMed Holdings as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Orchestra BioMed Holdings (OBIO) stock price performance year to date (YTD)?
As of the latest data, Orchestra BioMed Holdings (OBIO) has a year-to-date price change of -34.28%. Over the past month, the stock has experienced a price change of -1.03%. Over the last three months, the change has been -12.84%. Over the past six months, the figure is 10.54%.
help
Is Orchestra BioMed Holdings (OBIO) a profitable company?
Orchestra BioMed Holdings (OBIO) has a net income of -$49.12M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 93.26% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -1.66K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $2.76M, although specific revenue growth data is currently not available. The gross profit is $2.57M. Operating income is noted at -$51.51M. Furthermore, the EBITDA is -$59.81M.
help
What is the market capitalization of Orchestra BioMed Holdings (OBIO)?
Orchestra BioMed Holdings (OBIO) has a market capitalization of $218.25M. The average daily trading volume is 5.63, indicating the stock's liquidity and investor engagement.
News
Jun 24, 2024
Orchestra BioMed Holdings, Inc. (OBIO) Stock Jumps 7.3%: Will It Continue to Soar?
Jun 3, 2024
All You Need to Know About Orchestra BioMed Holdings, Inc. (OBIO) Rating Upgrade to Buy
Jun 3, 2024
Does Orchestra BioMed Holdings, Inc. (OBIO) Have the Potential to Rally 135.64% as Wall Street Analysts Expect?
CALENDAR OF EVENTS
CONFERENCE CALLS/ WEBCASTS
Orchestra BioMed to Participate in Jefferies Global Healthcare Conference
May 13, 2024
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Misses Revenue Estimates
EARNINGS RELEASES AND OPERATING RESULTS
Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update